Viktor Rotbain Curovic

Viktor Rotbain Curovic

Auto-generated profile, based on publicly available information

Viktor Rotbain Curovic

Steno Diabetes Center Copenhagen, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2020 in Diabetes
Verified
Journal Article
Closed access
PDF file
VCViktor Rotbain Curovic
Viktor Rotbain Curovic
TSTommi Suvitaival
Tommi Suvitaival
IMIsmo Mattila
Ismo Mattila
LALinda Ahonen
Linda Ahonen
KTKajetan Trošt
Kajetan Trošt
PRPeter Rossing
Peter Rossing
Omics-based methods may provide new markers associated to diabetic retinopathy (DR). We investigated a wide omics panel of metabolites and lipids related to DR in type 1 diabetes. Metabolomic analyses were performed using two-dimensional gas chromatography with time-of-flight mass spectrometry and lipidomic analyses using an ultra-high-performance liquid chromatography quadruple time-of-flight mass spectrometry method in 648 individuals with type 1 diabetes. Subjects were subdivided into no DR, mild nonproliferative DR (NPDR), moderate NPDR, proliferative DR, and proliferative DR with fibrosis. End points were any progression of DR, onset of DR, and progression from mild to severe DR tracked from standard ambulatory care and investigated using Cox models. The cohort consisted of 648 participants aged a mean of 54.4 ± 12.8 years, 55.5% were men, and follow-up was 5.1–5.5 years. Cross-sectionally, 2,4-dihydroxybutyric acid (DHBA), 3,4-DHBA, ribonic acid, ribitol, and the triglycerides 50:1 and 50:2 significantly correlated (P < 0.042) to DR stage. Longitudinally, higher 3,4-DHBA was a risk marker for progression of DR (n = 133) after adjustment (P = 0.033). We demonstrated multiple metabolites being positively correlated to a higher grade of DR in type 1 diabetes and several triglycerides being negatively correlated. Furthermore, higher 3,4-DHBA was an independent risk marker for progression of DR; however, confirmation is required.

18 March 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
VCViktor Rotbain Curovic
Viktor Rotbain Curovic
STSimone Theilade
Simone Theilade
SWSigne A. Winther
Signe A. Winther
NTNete Tofte
Nete Tofte
JEJesper Eugen-Olsen
Jesper Eugen-Olsen
PRPeter Rossing
Peter Rossing
OBJECTIVE Soluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However, suPAR’s predictive qualities for complications in type 1 diabetes have yet to be determined. We investigated the prognostic value of suPAR for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS We included 667 patients with type 1 diabetes with various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2–6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling of suPAR with 95% CI. Relative integrated discrimination improvement (rIDI) was calculated. RESULTS Quantification of suPAR was available in all participants; median (interquartile range) was 3.4 ng/mL (2.7–4.5). The adjusted HR (95% CI) for cardiovascular events (n = 94), progression in albuminuria (n = 36), eGFR decline (n = 93), ESRD (n = 23), and mortality (n = 58) were 3.13 (1.96–5.45, P < 0.001), 1.27 (0.51–3.19, P = 0.61), 2.93 (1.68–5.11, P < 0.001), 2.82 (0.73–11.9, P = 0.13), and 4.13 (1.96–8.69, P < 0.001), respectively. rIDI was significant for cardiovascular events (22.6%, P < 0.001), eGFR decline (14.4%, P < 0.001), and mortality (23.9%, P < 0.001). CONCLUSIONS In patients with type 1 diabetes and a broad range of albuminuria, a higher level of suPAR is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition, suPAR contributes significantly to discrimination for the end points.

18 September 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
SSSuvanjaa Sivalingam
Suvanjaa Sivalingam
VWVictor Soendergaard Wasehuus
Victor Soendergaard Wasehuus
VCViktor Rotbain Curovic
Viktor Rotbain Curovic
MBMartin Bæk Blond
Martin Bæk Blond
THTine Hansen
Tine Hansen
PRPeter Rossing
Peter Rossing
Aim: To investigate whether combined treatment with empagliflozin (a sodium‐glucose cotransporter‐2 inhibitor) and semaglutide (a glucagon‐like peptide‐1 receptor agonist) can reduce urinary albumin‐creatinine ratio (UACR) compared to treatment with empagliflozin alone in individuals with type 2 diabetes (T2D) and albuminuria. Methods: We conducted a randomized, placebo‐controlled, double‐blind, parallel study including 60 individuals with T2D and albuminuria. All participants initiated open‐label empagliflozin 25 mg once daily, on top of renin‐angiotensin system inhibition, in a run‐in period of 26 weeks. Subsequently, participants were randomized to semaglutide or placebo 1 mg once weekly for 26 weeks. The primary endpoint was change in UACR. Secondary endpoints were change in: (i) measured glomerular filtration rate (GFR); (ii) 24‐hour systolic blood pressure; (iii) glycated haemoglobin (HbA1c) level; (iv) body weight; and (v) plasma renin and aldosterone levels. Results: Addition of semaglutide to empagliflozin provided no additional change in UACR from randomization to end‐of‐treatment. The mean (95% confidence interval) difference in UACR was –22 (–44; 10)% ( P = 0.15) between treatment groups. Neither GFR, 24‐hour blood pressure, body weight, nor plasma renin activity was changed with semaglutide. HbA1c (–8 [–13; –3] mmol/mol; P = 0.003) and plasma aldosterone (–30 [–50; –3] pmol/L; P = 0.035) were reduced with semaglutide compared to placebo. Conclusions: Semaglutide added to empagliflozin did not change UACR, measured GFR, 24‐hour systolic blood pressure, body weight or plasma renin levels in individuals with T2D and albuminuria. Semaglutide improved glycaemic control and plasma aldosterone levels compared to placebo.

14 August 2018 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
VCViktor Rotbain Curovic
Viktor Rotbain Curovic
THTine Hansen
Tine Hansen
MEMie Eickhoff
Mie Eickhoff
BSBernt Johan von Scholten
Bernt Johan von Scholten
HRHenrik Reinhard
Henrik Reinhard
PRPeter Rossing
Peter Rossing

13 September 2021 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
EZEmilie Hein Zobel
Emilie Hein Zobel
AWAsger Wretlind
Asger Wretlind
RRRasmus Sejersten Ripa
Rasmus Sejersten Ripa
VCViktor Rotbain Curovic
Viktor Rotbain Curovic
BSBernt J von Scholten
Bernt J von Scholten
PRPeter Rossing
Peter Rossing
Introduction: Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can reduce risk of cardiovascular disease (CVD) in persons living with type 2 diabetes, however the mechanisms explaining this cardiovascular benefit are still debated. We investigated changes in the plasma lipidome following treatment with the GLP-1 RA liraglutide. Research design and methods: In a double-blind placebo-controlled trial, we randomized 102 persons with type 2 diabetes to liraglutide or placebo for 26 weeks. Fasting blood plasma was collected at baseline and at end-of-treatment. The lipidome was measured using liquid-chromatography-coupled mass-spectrometry as a secondary end point in the study. Treatment response of each lipid was tested with lipid-specific linear mixed-effect models comparing liraglutide with placebo. Bonferroni p<7.1e-03 was employed. The independence of the findings from clinical covariates was evaluated with adjustment for body mass index, HbA1c, fasting status, lipid-lowering treatment and change in lipid-lowering treatment during the trial. Results: In total, 260 lipids were identified covering 11 lipid families. We observed significant decreases following liraglutide treatment compared with placebo in 21 lipids (p<7.1e-03) from the following lipid families: ceramides, hexocyl-ceramides, phosphatidylcholines, phosphatidylethanolamines and triglycerides. We confirmed these findings in adjusted models (p≤0.01). In the liraglutide-treated group, the individual lipids were reduced in the range of 14%–61% from baseline level, compared with 19% decrease to 27% increase from baseline level in the placebo group. Conclusions: Compared with placebo, liraglutide treatment led to a significant downregulation in ceramides, phospholipids and triglycerides, which all are linked to higher risk of CVD. These findings were independent of relevant clinical covariates. Our findings are hypothesis generating and shed light on the biological mechanisms underlying the cardiovascular benefits observed with GLP-1 RAs in outcome studies, and further strengthen the evidence base for recommending GLP-1 RAs to prevent CVD in type 2 diabetes. Trial registration number: NCT03449654.

23 August 2022 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
VCViktor Rotbain Curovic
Viktor Rotbain Curovic
MEMie Klessen Eickhoff
Mie Klessen Eickhoff
TRTeemu Rönkkö
Teemu Rönkkö
MFMarie Frimodt-Møller
Marie Frimodt-Møller
THTine Willum Hansen
Tine Willum Hansen
FPFrederik Persson
Frederik Persson
OBJECTIVE: To evaluate the effect of the sodium–glucose cotransporter 2 inhibitor dapagliflozin on the kidney-risk urinary proteomic classifier (CKD273) in persons with type 2 diabetes (T2D) and albuminuria.RESEARCH DESIGN AND METHODS: In a double-blind, randomized, controlled, crossover trial, we assigned participants with T2D and urinary albumin to creatinine ratio (UACR) ≥30 mg/g to receive dapagliflozin or matching placebo added to guideline-recommended treatment (ClinicalTrials.gov identifier NCT02914691). Treatment periods lasted 12 weeks, when crossover to the opposing treatment occurred. The primary outcome was change in CKD273 score. Secondary outcomes included regression from high-risk to low-risk CKD273 pattern using the prespecified cutoff score of 0.154. The primary outcome was assessed using paired t test between end-to-end CKD273 scores after dapagliflozin and placebo treatment. The McNemar test was used to assess regression in risk category.RESULTS: A total of 40 participants were randomized and 32 completed the trial with intact proteomic measurements. Twenty-eight (88%) were men, the baseline mean (SD) age was 63.0 (8.3) years, mean (SD) diabetes duration was 15.4 (4.5) years, mean HbA1c was 73 (14) mmol/mol (8.8% [1.3%]), and median (interquartile range) UACR was 154 (94, 329) mg/g. Dapagliflozin significantly lowered CKD273 score compared with placebo (−0.221; 95% CI −0.356, −0.087; P = 0.002). Fourteen participants exhibited a high-risk pattern after dapagliflozin treatment compared with 24 after participants placebo (P = 0.021).CONCLUSIONS: Dapagliflozin added to renin-angiotensin system inhibition reduced the urinary proteomic classifier CKD273 in persons with T2D and albuminuria, paving the way for the further investigation of CKD273 as a modifiable kidney risk factor.